title: [Selected CD34+ cell autologous transplantation for advanced malignant tumors].
abstract: OBJECTIVE
  To determine the clinical results of selected CD34(+) cell autologous transplantation in advanced malignant tumors.
  
  
  METHODS
  After pretreatment, fifteen patients aged 12 - 70 (49.5) years with various Stage III or IV malignant tumors were given the sorted CD34(+) cells collected by magnetic-activated cell sorting (Clini MACS, Milteny Biotech, Germany).
  
  
  RESULTS
  Peripheral blood progenitor cells (PBPC) from the patients were mobilized by chemotherapy and G-CSF 5 micro g/kg per day. CD34(+) cells gave 2.0 - 5 log depletion after cell sorting, with a median yield of CD34(+) selected cells of 2.4 (0.15 - 12.03) x 10(6)/kg. It gave a median recovery of 64 (52 - 81.4)% and median purity of 98.2 (83.2 - 99.7)%. The median time of neutrophil recovery > 1.0 x 10(9)/L and platelet recovery > 20 x 10(9)/L post-transplantation were 14 (8 - 26) days and 13 (11 - 35) days, respectively. On follow-up of 2 - 33 (11) months, the event-free survival rate was 53.3% (8/15) and the overall survival rate was 66.7% (10/15).
  
  
  CONCLUSIONS
  Transplantation of autologous selected PBPC CD34(+) cells gives prompt and stable engraftment. Selected CD34(+) cell transplantation, being a safe approach, may improve the clinical outcome even in patients with advanced malignant tumors.
authors.affiliation: Hematopoietic Cell Transplantation Center, North Taiping Hospital, Beijing 100039, China.
authors.forename: Lu-jia
authors.initials: LJ
authors.lastname: Dong
authors.forename: Hu
authors.initials: H
authors.lastname: Chen
authors.forename: Min
authors.initials: M
authors.lastname: Jiang
authors.forename: Liang-ding
authors.initials: LD
authors.lastname: Hu
authors.forename: Mao-quan
authors.initials: MQ
authors.lastname: Qin
authors.forename: Wei-jing
authors.initials: WJ
authors.lastname: Zhang
authors.forename: Zhi-yong
authors.initials: ZY
authors.lastname: Yu
authors.forename: Shi-kai
authors.initials: SK
authors.lastname: Wu
authors.forename: Xi-lin
authors.initials: XL
authors.lastname: Chen
authors.forename: Yun-hua
authors.initials: YH
authors.lastname: Bao
authors.forename: San-tai
authors.initials: ST
authors.lastname: Song
authors.forename: Duan-qi
authors.initials: DQ
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis*; D002648:Child; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34